Atara Biotherapeutics (NASDAQ:ATRA) Stock Rating Upgraded by RODMAN&RENSHAW

Atara Biotherapeutics (NASDAQ:ATRA) was upgraded by analysts at RODMAN&RENSHAW to a “strong-buy” rating in a research report issued to clients and investors on Friday,Zacks.com reports.

A number of other equities analysts have also recently commented on the company. Rodman & Renshaw began coverage on Atara Biotherapeutics in a report on Friday. They set a “buy” rating and a $25.00 price target for the company. TD Cowen upgraded Atara Biotherapeutics to a “strong-buy” rating in a research note on Friday, November 29th. Finally, Canaccord Genuity Group boosted their target price on Atara Biotherapeutics from $13.00 to $21.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, three have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, Atara Biotherapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $18.75.

Atara Biotherapeutics Price Performance

NASDAQ:ATRA opened at $11.40 on Friday. The stock has a market cap of $65.66 million, a P/E ratio of -0.44 and a beta of 0.55. Atara Biotherapeutics has a 1-year low of $6.50 and a 1-year high of $39.50. The firm has a 50-day moving average of $10.80 and a two-hundred day moving average of $9.57.

Atara Biotherapeutics (NASDAQ:ATRA) last issued its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported ($2.93) earnings per share for the quarter, beating analysts’ consensus estimates of ($3.77) by $0.84. The company had revenue of $40.19 million during the quarter, compared to the consensus estimate of $23.00 million. During the same period last year, the company earned ($16.50) earnings per share. As a group, equities analysts expect that Atara Biotherapeutics will post -12.12 earnings per share for the current year.

Institutional Investors Weigh In On Atara Biotherapeutics

A number of hedge funds have recently added to or reduced their stakes in the company. Vestal Point Capital LP raised its stake in shares of Atara Biotherapeutics by 11.3% in the 3rd quarter. Vestal Point Capital LP now owns 124,677 shares of the biotechnology company’s stock valued at $1,014,000 after acquiring an additional 12,677 shares during the period. Geode Capital Management LLC lifted its stake in shares of Atara Biotherapeutics by 9.5% in the 3rd quarter. Geode Capital Management LLC now owns 46,720 shares of the biotechnology company’s stock valued at $380,000 after purchasing an additional 4,043 shares during the last quarter. FMR LLC lifted its holdings in shares of Atara Biotherapeutics by 41.7% during the third quarter. FMR LLC now owns 25,061 shares of the biotechnology company’s stock worth $204,000 after buying an additional 7,381 shares during the last quarter. State Street Corp grew its stake in shares of Atara Biotherapeutics by 52.3% in the 3rd quarter. State Street Corp now owns 22,353 shares of the biotechnology company’s stock valued at $182,000 after purchasing an additional 7,680 shares during the period. Finally, Cubist Systematic Strategies LLC acquired a new position in shares of Atara Biotherapeutics during the second quarter worth approximately $79,000. Institutional investors and hedge funds own 70.90% of the company’s stock.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.